ArticleGastro hep advances2026
Recompensation in Patients With Alcohol-Related Liver Disease-A Multicenter Study.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recompensation as a Clinical End Point in Alcohol-Associated Cirrhosis: Gaps in Evidence and Priorities Ahead of Baveno VIII.Gastro hep advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Removal of etiology of cirrhosis may lead to recompensation in decompensated cirrhosis. Few studies have reported on rates of recompensation, as per Baveno VII criteria, in viral etiology-related decompensated cirrhosis. Our aim was to assess the rate and predictors of recompensation in the spectrum of alcohol-related liver disease (ALD). Methods: Retrospective multicenter cohort study across 5 Indian centers included patients with a spectrum of ALD from January 2018 to November 2024. Clinical and biochemical data were collected and patients followed, and end points of recompensation, mortality, and transplant-free survival were evaluated. Results: Among 344 patients (age: 41.2 ± 8.4 years; Model for End-Stage Liver Disease: 23.9 ± 6.2; men: 98.3%), 242 had decompensated cirrhosis with alcohol-associated hepatitis (DC + AAH), and 102 had decompensated cirrhosis without alcohol-associated hepatitis (DC-AAH). Twenty percent (69/344) achieved recompensation as per Baveno VII criteria over 21 (range, 12-67) months. The recompensation rate was higher among those with DC-AAH (30.4%; 31/102) compared to DC + AAH (15.7%; 38/242; Conclusion: Twenty percent of patients in the spectrum of ALD demonstrated recompensation, which was associated with improved survival.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.